Repositorio Dspace

ListarEnfermedades Desmielinizantes.artículos por tema "Inmunosupresores"

ListarEnfermedades Desmielinizantes.artículos por tema "Inmunosupresores"

Ordenar por:Orden:Resultados:

  • A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study 
    Giovannoni, Gavin; Boyko, Alexey; Correale, Jorge; Edan, Gilles; Freedman, Mark S.; Montalban, Xavier; Rammohan, Kottil; Stefoski, Dusan; Yamout, Bassem; Leist, Thomas; Aydemir, Aida; Borsi, Laszlo; Verdun di Cantogno, Elisabetta (Future Medicine, 2023-08-03)
    What is this summary about?: Previous studies have shown that people living with multiple sclerosis (MS) treated with cladribine tablets have fewer relapses (where new symptoms occur or existing symptoms get worse for 24 ...
  • Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study 
    Giovannoni, Gavin; Boyko, Alexey; Correale, Jorge; Edan, Gilles; Freedman, Mark S.; Montalban, Xavier; Rammohan, Kottil; Stefoski, Dusan; Yamout, Bassem; Leist, Thomas; Aydemir, Aida; Borsi, Laszlo; Verdun di Cantogno, Elisabetta (Sage, 2023-04-03)
    Background: CLASSIC-MS evaluated the long-term efficacy of cladribine tablets in patients with relapsing multiple sclerosis. Objective: Report long-term mobility and disability beyond treatment courses received in ...
  • Rebound activity after fingolimod cessation: A case - control study 
    Barboza, Andrés G.; Gaitán, María Inés; Alonso, Ricardo; Ysrraelit, María Célica; Luetic, Geraldine G.; Liwacki, Susana; Patrucco, Liliana; Halfon, Mario Javier; Burgos, Marcos; Mainella, Carolina; Piedrabuena, Raúl; Recchia, Luciano; Steinberg, Judith; Tkachuk, Verónica A.; Zanga, Gisela; Carra, Adriana; Chertcoff, Aníbal; Fernández Liguori, Nora; Lázaro, Luciana; Menichini, María Laura (Elsevier, 2022-02-09)
    Background: There has been an increase in the number of reports of multiple sclerosis (MS) rebound activity (RA), which is usually defined as a severe disease reactivation after natalizumab or fingolimod withdrawal that ...

Buscar en DSpace


Listar

Mi cuenta